--- title: "NeOnc Technologies Holdings (NTHI) news: going concern and IPO" url: "https://aibio.space/companies/neonc-technologies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NTHI going concern, IPO and offering news: NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale." --- NTHI NeOnc Technologies Holdings, Inc. NASDAQ · United States # NeOnc Technologies Holdings (NTHI) news NTHI going concern, IPO and offering news Distress · 2025-08-14 ## [NeOnc Technologies delays quarterly report to finish review of stock unit charges](https://aibio.space/news/neonc-technologies-delays-quarterly-report-finish-review-stock-unit/) NeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days. ## Latest NeOnc Technologies Holdings news 1. 2025-08-01 Mergers [NeOnc Technologies signs up to $50 million investment deal with Quazar at $25 per share](https://aibio.space/news/neonc-technologies-signs-up-50-million-investment-deal-quazar-25-share/) Quazar Investment would buy 1.4 million shares and fund trials and infrastructure in the UAE and MENA region. Closing still depends on a capital formation round. 2. 2025-03-25 Financings [NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale](https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/) NeOnc's prospectus registers 2,101,313 shares for resale in a Nasdaq direct listing, and the company gets none of the proceeds. Its financial advisor RBW Capital Partners is also the placement agent for a $10 million private placement, and the auditor's report carries a going concern paragraph. ## NeOnc Technologies Holdings at a glance - **Ticker**: NTHI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $2.0 million ### Related companies - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) NASDAQ: EWTX - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP - [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTC: OTLC - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [Novavax](https://aibio.space/companies/novavax/) NASDAQ: NVAX - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) NASDAQ: PMVP - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW ### Also on NASDAQ - [Valion Bio](https://aibio.space/companies/valion-bio/) VBIO - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) ADIL - [Eton Pharmaceuticals](https://aibio.space/companies/eton-pharmaceuticals/) ETON - [Exicure](https://aibio.space/companies/exicure/) XCUR - [Acurx Pharmaceuticals](https://aibio.space/companies/acurx-pharmaceuticals/) ACXP - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX ## NeOnc Technologies Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$39,990](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | [$83,000](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | | Research and development | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | | Net income (loss) | [-$62.1 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | [-$11.9 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | | Cash from operations | [-$20.4 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | | Cash and equivalents | [$58,729](https://www.sec.gov/Archives/edgar/data/1979414/000182912626008512/) | [$64,893](https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NeOnc Technologies Holdings Has NeOnc Technologies Holdings issued a going-concern warning? Our latest story on this, dated Mar 25, 2025: "NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/). When did NeOnc Technologies Holdings go public? Our latest story on this, dated Mar 25, 2025: "NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/). Has NeOnc Technologies Holdings raised money recently? Our latest story on this, dated Mar 25, 2025: "NeOnc Technologies sets Nasdaq direct listing, registers 2,101,313 shares for resale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/). What is the ticker symbol of NeOnc Technologies Holdings? NeOnc Technologies Holdings, Inc. trades under the ticker NTHI on NASDAQ. Where is NeOnc Technologies Holdings listed? NeOnc Technologies Holdings, Inc. is listed on NASDAQ. What is the SEC CIK of NeOnc Technologies Holdings? The SEC Central Index Key (CIK) for NeOnc Technologies Holdings, Inc. is 1979414. Its filings are on SEC EDGAR. How many shares does NeOnc Technologies Holdings have outstanding? 25,936,365 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is NeOnc Technologies Holdings listed under? Our directory records NeOnc Technologies Holdings, Inc. under United States. What does NeOnc Technologies Holdings do? Our directory classifies NeOnc Technologies Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of NeOnc Technologies Holdings? The ISIN recorded for NeOnc Technologies Holdings, Inc. is US64051A1016. Does aibio.space cover NeOnc Technologies Holdings? aibio.space lists NeOnc Technologies Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NeOnc Technologies Holdings incorporated? SEC records list its state or country of incorporation as DE. What was NeOnc Technologies Holdings's revenue last year? $39,990 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is NeOnc Technologies Holdings profitable? NeOnc Technologies Holdings, Inc. reported a net loss of $62.1 million for the fiscal year ended Dec 31, 2025, and used $20.4 million of cash in operations, per its annual report to the SEC. How much does NeOnc Technologies Holdings spend on research and development? $3.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: NeOnc Technologies Holdings Members talk about NeOnc Technologies Holdings (NTHI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NeOnc Technologies Holdings, newest first. Each line links the filing it comes from. 1. 2026-09-21 Financings Reported a financing. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912626010282/neonctechnologies_ex99-1.htm) 2. 2026-09-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912626009976/neonctechnologies_424b5.htm) 3. 2026-06-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912626006400/neonctechnologies_8k.htm) 4. 2026-04-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912626003400/neonctechnologies_424b5.htm) 5. 2025-12-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625009754/neonctechnologies_ex99-1.htm) 6. 2025-11-13 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625009130/neonctechnologies_424b4.htm) 7. 2025-08-18 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625006425/neonctechnologies_8k.htm) 8. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625006332/neonctech_nt10q.htm) 9. 2025-08-01 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625005708/neonctechnologies_ex99-1.htm) 10. 2025-07-22 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625005280/neonctechnologies_8k.htm) 11. 2025-06-16 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625004527/neonctechnologies_424b5.htm) 12. 2025-05-09 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625003527/neonctechnologies_10q.htm) 13. 2025-04-01 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625002294/neonctechnologies_8k.htm) 14. 2025-03-25 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1979414/000182912625002051/neonctechnologies_424b4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NTHI on TradingView](https://www.tradingview.com/symbols/NASDAQ-NTHI/). ## SEC filings and registration - **SEC name**: Neonc Technologies Holdings, Inc. - **CIK**: 1979414 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NTHI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 23975 PARK SORRENTO, CALABASAS, CA, 91302 - **Phone**: 310 663 7831 - **Shares outstanding**: 25,936,365 as of 2026-08-10 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626011446/neonctechnologies_8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626011189/neonctechnologies_8k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626010493/neonctechnologies_8k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626010282/neonctechnologies_8k.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626010156/neonctechnologies_8k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626009977/neonctechnologies_8k.htm) filed 2026-09-10 - [424B5](https://www.sec.gov/Archives/edgar/data/1979414/000182912626009976/neonctechnologies_424b5.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1979414/000182912626009103/neonctechnologies_8k.htm) filed 2026-08-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001979414), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NeOnc Technologies Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NTHI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NeOnc Technologies Holdings, Inc. - **Ticker**: NTHI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US64051A1016 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NTHI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/neonc-technologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NeOnc Technologies Holdings (NTHI) news: going concern and IPO", 2026-10-31, https://aibio.space/companies/neonc-technologies/